Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.

BMC pulmonary medicine - 22 Jun 2023

Hu Xilin, Guo Jing, Shi Jianguang, Li Da, Li Xinjian, Zhao Weijun

Abstract excerpt

BACKGROUND: There is an unmet need to identify novel predictive biomarkers that enable more accurate identification of individuals who can benefit from immune checkpoint inhibitor (ICI) therapy. The US FDA recently approved tumor mutational burden (TMB) score of ≥ 10 mut/Mb as a threshold for pembrolizumab treatment of solid tumors. Our study aimed to test the hypothesis that specific gene mutation signature may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 37349743
DOI: 10.1186/s12890-023-02512-6
PMCID: PMC10288780

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.PMID 37349743Read ↗

A Predictive Model for Evaluating Efficacy of Immunotherapy in Non-small-cell Lung Cancer PatientsSemantic proximity Read ↗

A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.Semantic proximity Read ↗

Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma.Semantic proximity Read ↗

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read ↗

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read ↗

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read ↗

Prognostic value of tumor mutation burden in non-small cell lung cancer: A Meta-Analysis and system reviewSemantic proximity Read ↗

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.Semantic proximity Read ↗

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.